Navigation Links
Biomoda, Inc. and Quintiles Announce Agreement for Regulatory Consulting
Date:9/10/2007

ALBUQUERQUE, N.M., Sept. 10 /PRNewswire-FirstCall/ -- Biomoda, Inc. (OTC Bulletin Board: BMOD) (http://www.biomoda.com) of Albuquerque, N.M., maker of early lung cancer detection testing and other cancer diagnostic technology, announced today an agreement with Quintiles Consulting of Rockville, Md., for regulatory consulting and design of clinical studies of Biomoda's proprietary test for detection of early lung cancer as part of the company's clinical programs.

"Quintiles has the experience, skills and understanding of the full range of review perspectives that bear on agency evaluations of new medical tests and devices," said John Cousins, President of Biomoda. "They will provide guidance, input and review to structure protocol, data content and collection and other information relative to making sure information is gathered in appropriate formats for future FDA submittals by our company."

Quintiles Consulting (http://www.quintiles.com) is the regulatory consulting unit of Quintiles Transnational Corp, a global corporation powering the next generation of healthcare by providing a broad range of professional services in product development, financial partnering and commercialization for the pharmaceutical, biotechnology and medical device industries. Quintiles Consulting helps companies navigate regulatory challenges and improve efficiencies from early discovery through commercialization. Among its services, Quintiles Consulting provides advice and strategies in the areas of product development, regulatory submissions and compliance, bioresearch monitoring, quality systems, validation, and pricing and reimbursement.

Biomoda's technology is based on a patented porphyrin application that preferentially binds to cancerous or aberrant cells extracted from lung sputum samples. Cancerous cells glow red under fluorescent light to allow detection under a microscope. The patented technology, a non-invasive cytology based assay, is designed for cancer screening of large populations at a reasonable cost. Current diagnostic methods for lung cancer, including CT scans and X- rays, often detect the disease only at more advanced stages and are relatively expensive.

Lung cancer claims more lives than any other cancer. The expected 5-year survival rate for all patients combined in whom lung cancer is diagnosed is 15 percent and by contrast, the 5-year survival rate for cases detected when the disease is still localized is 50 percent. At the present time, only 16 percent of lung cancer cases are diagnosed at this early stage.

Cautionary Statement: Investors should be aware that trading in the company's stock through market makers and quotation on the OTC Bulletin Board entails risk. Due in part to the decreased trading price of our stock and reduced analyst coverage, the trading price may change quickly, and market makers may not be able to execute trades quickly. Please contact your broker if you have further questions about executing trades. "Safe Harbor" Statement: This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are naturally subject to uncertainty and changes in circumstances. Actual results may vary materially from expectations contained herein. Biomoda is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Biomoda, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. PM announces a new health care order for India
2. Partnership Between Diabetes India And Elsevier Announced
3. US Politicians Urge Movie Moghuls To Add Anti-Smoking Announcements
4. OHSU Researchers Announce New Discovery
5. PowderMed Announces Needle-Less Flu Vaccine
6. Ramdoss Announces Introduction of RCH-II
7. Britain Announces Third Transfusion Related Mad Cow Case
8. Tibet Announces the Dalai Lama’s Tour of South Americ
9. NHS announces further Cost cutting Measures
10. Indian PM Announces Of Setting Up India Study Center At Tashkent
11. Chiefs Of Regional Commissions For Animal Health Announced
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2017)... San Mateo, CA (PRWEB) , ... February 26, 2017 , ... ... Bay Area cities as diverse as Millbrae, Belmont, and Palo Alto, is proud to ... San Mateo. Many Bay Area consumers look for home care close to home, and ...
(Date:2/26/2017)... ... February 26, 2017 , ... ... in staffing, scheduling, and reporting for healthcare organizations. This comprehensive and customizable ... entire staffing process. StaffBridge technology improves staffing efficiency, maximizes resource allocation, collects ...
(Date:2/26/2017)... Florida (PRWEB) , ... February 26, 2017 , ... ... of Parkinson’s disease (PD) in persons with a specific LRRK2 mutation, according to ... Congress. , Previous studies have provided evidence of a link between pesticides and ...
(Date:2/24/2017)... , ... February 24, 2017 , ... ... on tooth replacement options at his office, Antoine Dental Center. Currently, patients can ... $18,499. Some restrictions may apply, but patients can learn more about these offers ...
(Date:2/24/2017)... ... February 24, 2017 , ... An in-depth computational analysis of genetic variants ... points to eight genes that may explain why susceptibility to one of the disorders ... a study published today in the journal npj Schizophrenia. , “There is a ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... Research and Markets has announced the addition ... Industry Forecast to 2025" report to their offering. ... The Global Wireless Health ... over the next decade to reach approximately $330.5 billion by 2025. ... for all the given segments on global as well as regional ...
(Date:2/24/2017)... 2017 Research and Markets has announced the addition ... report to their offering. ... The latest research Dry eye Drugs Price Analysis and Strategies - ... market. The research answers the following questions: ... clinical attributes? How are they positioned in the Global Dry eye market? ...
(Date:2/24/2017)... Juan Monteverde , founder and managing ... boutique securities firm headquartered at the Empire State Building ... that a class action lawsuit has been filed in the ... Inotek Pharmaceuticals Corporation (NASDAQ:  ITEK)("Inotek" or the "Company") on ... 2015 and December 30, 2016, inclusive (the "Class Period").  ...
Breaking Medicine Technology: